Sareum Holdings PLC Sareum notes Sierra Oncology Q2 2018 Results (3716X)
August 09 2018 - 8:15AM
UK Regulatory
TIDMSAR
RNS Number : 3716X
Sareum Holdings PLC
09 August 2018
(AIM: SAR) 9 August 2018
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Sareum notes Sierra Oncology has reported Second Quarter
Results
Sareum Holdings plc (AIM: SAR), the specialist cancer drug
discovery and development business, notes that Sierra Oncology, the
licence holder advancing clinical cancer candidate SRA737, has
reported its Second Quarter Results including reference to the
ongoing development of SRA737.
"We continue to advance our lead drug candidate, SRA737, across
three distinct clinical development strategies; as a monotherapy,
in combination with low dose gemcitabine, and in combination with a
PARP inhibitor. During the second quarter, we further refined our
monotherapy study to focus on high grade serous ovarian cancer
(HGSOC), supported by emerging data in the field that provides
clinical validation for Chk1 inhibition in this indication.
Accordingly, we are prioritizing the enrollment of approximately 65
genetically defined HGSOC patients into this trial, while
continuing to enroll patients into the trial's other indications,
although with lower priority," said Dr. Nick Glover, President and
CEO of Sierra Oncology. "However, given that this amendment will
require time to operationalize, we anticipate preliminary data from
our monotherapy trial will be reported in the first half of
2019."
Sierra is now also planning to include and prioritize for
ovarian cancer patients in its combination trial of SRA737
potentiated by low dose gemcitabine. The company recently reported
having commenced the Cohort Expansion Phase 2 portion of this
trial, which is targeting enrollment of 80 patients across four
indications. Sierra plans to modify this study to add and
prioritize enrollment for a cohort of 20 genetically defined HGSOC
patients, replacing an originally proposed cohort of urothelial
cancer patients. Preliminary data from this trial is now also
anticipated to be reported in the first half of 2019.
Title of announcement: Sierra Oncology Reports Second Quarter
Results
Link to announcement:
https://www.prnewswire.com/news-releases/sierra-oncology-reports-second-quarter-results-300694220.html
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser)
Chris Fielding / James Sinclair-Ford 020 7220 1666
Hybridan LLP (Broker)
Claire Noyce 020 3764 2341
Citigate Dewe Rogerson (Media
enquiries)
Shabnam Bashir/ Mark Swallow/
David Dible 020 7638 9571
Notes for editors:
About Sareum
Sareum is a specialist drug discovery and development company
delivering targeted small molecule therapeutics, focusing on cancer
and autoimmune disease, and generating value through licensing them
to international pharmaceutical and biotechnology companies at the
preclinical or early clinical trials stage.
Its most advanced programme, SRA737, is a novel Checkpoint
kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology
and in Phase 1/2 clinical trials targeting a range of advanced
cancers. The key role of Chk1 in cancer cell replication and DNA
damage repair suggests that SRA737 may have broad application as a
targeted monotherapy and in combination with other oncology and
immuno-oncology drugs in genetically defined patients.
Sareum is also advancing programmes to develop novel tyrosine
kinase 2 (TYK2) inhibitors in autoimmune diseases and cancers, and
Aurora+FLT3 inhibitors in haematological cancers, which are in the
candidate selection and IND-enabling preclinical stages.
The Company's drug discovery technology platform (SKIL(R) -
Sareum Kinase Inhibitor Library) has the potential to generate drug
research programmes against other kinase targets.
Sareum Holdings plc is quoted on the Alternative Investment
Market (AIM) of the London Stock Exchange, trading under the ticker
SAR. For further information, please visit www.sareum.co.uk.
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCSSFFEUFASEFA
(END) Dow Jones Newswires
August 09, 2018 08:15 ET (12:15 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2023 to Apr 2024